













Follow us:

facebook.com/mrskomiium



37 TH MSPP ANNUAL SCIENTIFIC MEETING in conjunction with

9TH MEDICAL RESEARCH SYMPOSIUM

ABSTRACT BOOK

INTEGRATING MISSION ORIENTED RESEARCH IN MEDICAL SCIENCES





WED & THU

11 & 12 SEPT 2024



TIME

8:00AM - 5:00PM



VENUE

AC HOTEL BY MARRIOTT KUANTAN, PAHANG, MALAYSIA P030

Role of DBP and FGG Proteins in Obese Schizophrenia: A Proteomic Study

SITI NORAIN MAT RASID¹, NOUR EL HUDA ABD RAHIM^{1*}, NORBAIYAH MOHAMED BAKRIM¹, MOHD ASYRAF ABDULL JALIL¹, NORLELAWATI A. TALIB², MOHD YUSRI IDORUS³, AHMAD NABIL MD. ROSLI⁴, MOHD ARIFIN KADERI⁵, NORAININ SOFIYA AZMAN²

¹Department of Basic Medical Science, Kulliyyah of Medicine, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang

²Department of Pathology and Laboratory Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang

³Institute of Medical Molecular Biotechnology, Faculty of Medicine, Universiti Teknologi MARA, Jalan Hospital, 47000 Sungai Buloh, Selangor

⁴Department of Psychiatry, Kulliyyah of Medicine, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang

⁵Department of Biomedical Science, Kulliyyah of Allied Health Sciences, International Islamic University Malaysia, Jalan Sultan Ahmad Shah, 25200 Kuantan, Pahang

*Corresponding author email: elhuda@iium.edu.my

Introduction: Both schizophrenia and obesity are complicated conditions that can have a major negative impact on an individual's health and quality of life. Even though each condition has been thoroughly researched on its own, the intersection of obesity in schizophrenia patients remains underexplored, particularly at the proteomic level. Using two-dimensional gel electrophoresis (2-DE) and liquid chromatography-mass spectrometry (LC-MS), this study aims to identify the differently expressed proteins in obese schizophrenia patients compared to obese non-schizophrenia controls. Materials and method: This comparative cross-sectional study used plasma samples from 20 subjects. Protein extracts from plasma samples of obese schizophrenia patients (n=10) and obese non-schizophrenia controls (n=10) were separated using 2-DE. Statistical analysis was performed using Independent Student's t-test to determine the protein expression patterns between groups using PD Quest Software. Then, the differently expressed protein spots were excised and identified via LC-MS. Results: The study identified two proteins with significant differential expression (p < 0.05) in obese schizophrenia patients compared to obese controls. Vitamin D binding protein (DBP) and Fibrinogen Gamma Chain (FGG) were found to be differently expressed. DBP is known for its role in metabolic regulation and immune response. While FGG involves in coagulation and inflammation processes, indicating a possible increase in cardiovascular risks including obesity. The different expressions of these proteins suggest potential disruptions in various metabolic and inflammatory pathways which could provide

insights into mechanisms linking obesity and schizophrenia. **Conclusion:** These findings highlight the distinct proteomic profile associated with obesity in schizophrenia patients. These proteins could serve as candidate biomarkers for understanding the pathophysiology underlying the comorbidity of obesity and schizophrenia. Further research is needed to discover the exact role of these proteins and their potential as therapeutic targets.

Keywords: Schizophrenia; obesity; proteomic analysis